ARCT Arcturus Therapeutics Holdings Inc

$ARCT arkg is buying more. Two days in a row. They’ve added nearly 40,000 shares. They have a big position already so really good news that they are adding.

$ARCT Upcoming catalysts for ARCT: Out-licensing the Seasonal Flu Phase 2-ready sa-mRNA quadrivalent vaccine , partnering the BARDA backed pandemic influenza asset, securing a regional commercial distributor for KOSTAIVE in Europe and the UK, Advancing KOSTAIVE toward U.S. BLA filing

$ARCT Posted this today in the PACB-Thread: Genetics is currently the “crème de la crème” of medical research. Only the most renowned research institutes, researchers, and university hospitals worldwide are working in this field. As mentioned in some of the posts here, examples are frequently cited of those who work with or use PACB’s systems. Widespread adoption is only a matter of time, as genetics will increasingly provide answers to the unknowns surrounding health and disease. As for my investment here, I’ll be patient and won’t let the ups and downs throw me off. Why I post it also here? Because Arcturus will deliver/provides the practical application. So let's stay patient and wait until the general public and the big players get on board here, too. Thanks to the users here who provide regular updates.

$ARCT If Arcturus is successful with 810 and 032…. 810 - revenue of 0.5 billion to more than 1 billion 032 - revenue of 1 billion to more than 2 billion Note that if 032 can also be for all the other CF patients, then, the potential revenue can be 1 billion to 5 billion plus Kostaive – 0.3 billion to 0.5 billion So, if all goes well, we may be looking at 2 billion to 6 billion plus revenue or more…. There are other programs in preclinical or phase 1..... Just my own opinion…..

$ARCT BioNTech $BNTX fell after its experimental mRNA cancer drug BNT113 missed key endpoint. Personally I believe Arcturus has much better platforms and technologies and it can develop better oncology therapies in the future….. So far I think Moderna $MRNA is racing ahead….

$ARCT The more I look into Arcturus and think about it, the more I’m convinced that this company—which is still relatively unknown at this stage but is making great strides with its mRNA approach—has a bright future ahead, unless a major player acquires it.

$ARCT Moderna at 90 B MC. ARCT at 295 M. OK, I understand, Moderna is a Bentley. But why is the Mercedes S-Class currently a gift?

$ARCT "Under the deal, Novartis will gain exclusive rights to Abogen's experimental ​drug, ABO2203, and options to license other therapies based on Abogen's RNA technology. Abogen will receive $575 million upfront with the potential to earn an additional $7.2 billion if the drug advances through development and wins regulatory approval." https://www.reuters.com/legal/litigation/novartis-strikes-about-78-billion-mrna-deal-with-chinas-abogen-2026-10-02/

$ARCT i believe some good news gonna be announced. they always keepin IT quiet. maybe going into phase 3 with arct032 maybe partnership, maybe both. :)

$ARCT "Arcturus' pipeline includes programs in cystic fibrosis (CF), ornithine transcarbamylase (OTC) deficiency, phenylketonuria (PKU) and Gout. Arcturus' versatile RNA therapeutics platforms can be applied toward multiple types of nucleic acid medicines including messenger RNA, small interfering RNA (siRNA), circular RNA, antisense RNA, self-amplifying RNA, DNA, and gene editing therapeutics. "

$ARCT we should be trading at least at $30. cmon ppl support the battle with cf!!!! Lots of ppl, young ones esp dying because of cf. i do think arct is very close to find a cure. lets fucking beat this f.... disease!!

$ARCT Until recently, Cathie Wood's AKRG ETF held about 2.7 million shares of Artc.. But suddenly it jumped to about 5.6 million shares. Even looking at the past data on the x(Twitter) Ark Invest Tracker, I couldn't find when this large-scale purchase was madeAnyway, if this isn't a typo, that's very surprising. No such large-volume buy order has occurred in the market; did they acquire the shares through over-the-counter trading..I simply don't know. If you know anything about this, I would appreciate it if you could share

$ARCT Leerink Partners maintains Outperform rating on Arcturus Therapeutics, $19 price target

$ARCT What about Lyme disease plus that bacterium Yersinia pestis that can originate from ticks residing on deers which are so many in my neighborhood? Yesinia pestis is usually transmitted from infected rodents but definitely men with ill-intention can inject the bacteria into deer population!

$ARCT Oftentimes despite any PR or good macro these gaps get filled. 80% of the time in fact. Nice rally but the big volume came in at $8 and so they wait before entering again.

$ARCT *gap fill watch Eleven days after posting ARCT closed at $8.21 and ran wicking just short of $18 multiple times.

$ARCT Per Grok: Yes, Arcturus Therapeutics’ self-amplifying mRNA COVID-19 vaccine (KOSTAIVE / ARCT-154 and updated versions) has demonstrated neutralizing antibody activity against the XFG (also called Stratus) strain in non-clinical studies, though it is not formulated as a monovalent vaccine specifically targeting only XFG.⁠ XFG (Stratus, sometimes called the “American” strain in media) is a recombinant Omicron-lineage SARS-CoV-2 variant (from LF.7 and LP.8.1.2 lineages). It was first identified around January 2025, has circulated widely (including becoming prominent in North America and the UK), and is monitored by the WHO as a variant under monitoring.

$ARCT Moderna with big success in mRNA cancer vaccine development. ARCT should also look out for a partner and concentrate on cancer vaccines. Thats where real money will be made!

$ARCT ARKG shares of ARCT: ARCTURUS THERAPEUTICS HOLDIN ARCT UQ 03969T109 3,016,199 $31,428,793.58 Looks to be corrected.

$ARCT 🇮🇳✈️🇺🇸 Came to America chasing the American Dream… apparently the dream was to leave with the IP. 💀😂🧬